{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:40:46Z","timestamp":1793122846986,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,2,9]],"date-time":"2015-02-09T00:00:00Z","timestamp":1423440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Roche Molecular Systems"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.ygyno.2015.01.551","type":"journal-article","created":{"date-parts":[[2015,2,7]],"date-time":"2015-02-07T19:50:01Z","timestamp":1423338601000},"page":"47-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":145,"title":["Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial"],"prefix":"10.1016","volume":"137","clinical-trial-number":[{"clinical-trial-number":"nct00709891","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Joseph","family":"Monsonego","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Thomas","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo L.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poh-Sin","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warner","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2015.01.551_bb0005","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0010","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.ygyno.2015.01.551_bb0015","author":"World Health Organization"},{"key":"10.1016\/j.ygyno.2015.01.551_bb0020","series-title":"European Guidelines for Quality Assurance in Cervical Cancer Screening","year":"2008"},{"key":"10.1016\/j.ygyno.2015.01.551_bb0025","doi-asserted-by":"crossref","first-page":"880","DOI":"10.7326\/0003-4819-156-12-201206190-00424","article-title":"US Preventive Services Task Force. Screening for cervical cancer: US Preventive Services Task Force recommendation statement","volume":"156","author":"Moyer","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0030","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1309\/AJCPTGD94EVRSJCG","article-title":"American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer","volume":"137","author":"Saslow","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0035","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1097\/01.AOG.0000438960.31355.9e","article-title":"Practice Bulletin No. 140: management of abnormal cervical cancer screening test results and cervical cancer precursors","volume":"122","author":"American College of Obstetrians and Gynecologists","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0040","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/dji187","article-title":"Elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice","volume":"97","author":"Khan","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0045","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/jnci\/djq356","article-title":"Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence","volume":"102","author":"Kj\u00e6r","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0050","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1309\/AJCPTUS5EXAS6DKZ","article-title":"Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results","volume":"136","author":"Wright","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0055","doi-asserted-by":"crossref","first-page":"184.e1","DOI":"10.1016\/j.ajog.2012.11.020","article-title":"Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16\/18: results from the ATHENA HPV study","volume":"208","author":"Cox","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0060","doi-asserted-by":"crossref","first-page":"46.e1","DOI":"10.1016\/j.ajog.2011.07.024","article-title":"The ATHENA human papillomavirus study: design, methods, and baseline results","volume":"206","author":"Wright","year":"2012","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0065","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1309\/AJCPZ5JY6FCVNMOT","article-title":"High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study","volume":"135","author":"Stoler","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0070","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/AOG.0000000000000458","article-title":"Relevance of random biopsy at the transformation zone when colposcopy is negative","volume":"124","author":"Huh","year":"2014","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0075","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.287.16.2114","article-title":"The 2001 Bethesda System: terminology for reporting results of cervical cytology","volume":"287","author":"Solomon","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2015.01.551_bb0080","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens\u2014part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0085","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/OLQ.0b013e318164e567","article-title":"Detection of human papillomavirus genotypes among high-risk women: a comparison of hybrid capture and linear array tests","volume":"35","author":"Monsonego","year":"2008","journal-title":"Sex. Transm. Dis."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0090","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/039463201102400115","article-title":"High risk human papillomavirus genotyping in clinical samples: evaluation of different commercial tests","volume":"24","author":"Paolini","year":"2011","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0095","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/JCM.02116-14","article-title":"A study of genotyping for the management of human papillomavirus-positive, cytology-negative cervical screening results","volume":"53","author":"Schiffman","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0100","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1002\/cncr.28548","article-title":"Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009","volume":"120","author":"Rositch","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2015.01.551_bb0105","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/ijc.27608","article-title":"A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination","volume":"132","author":"Wheeler","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2015.01.551_bb0110","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/infdis\/jir341","article-title":"Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003\u20132006","volume":"204","author":"Hariri","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0115","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1016\/j.vaccine.2012.06.013","article-title":"Prevalence of type-specific human papillomavirus infection among women in France: implications for screening, vaccination, and a future generation of multivalent HPV vaccines","volume":"30","author":"Monsonego","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.ygyno.2015.01.551_bb0120","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings","volume":"202","author":"Bruni","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0125","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/cncr.20877","article-title":"Mortality trends for cervical squamous and adenocarcinoma in the United States: relation to incidence and survival","volume":"103","author":"Sherman","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2015.01.551_bb0130","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(03)12120-4","article-title":"Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia","volume":"361","author":"Woodman","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2015.01.551_bb0135","series-title":"Modern Colposcopy","first-page":"325","article-title":"Colposcopy of adenocarcinoma in situ and adenocarcinoma of the uterine cervix","author":"Wright","year":"2011"},{"issue":"5 Suppl. 1","key":"10.1016\/j.ygyno.2015.01.551_bb0140","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1097\/LGT.0b013e31828543c5","article-title":"Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management","volume":"17","author":"Katki","year":"2013","journal-title":"J. Low. Genit. Tract Dis."},{"key":"10.1016\/j.ygyno.2015.01.551_bb0145","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ygyno.2010.12.361","article-title":"Characteristics of 44 cervical cancers diagnosed following Pap-negative, high risk HPV-positive screening in routine clinical practice","volume":"121","author":"Kinney","year":"2011","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815006034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815006034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:36:09Z","timestamp":1758771369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815006034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0090825815006034"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.01.551","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.01.551","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}